REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-04-30

Study Completion Date

2010-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Insulin will safely reduce glucose levels in patients with acute ST-elevation myocardial infarction and admission hyperglycemia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD)

NCT01035528

Coronary Artery Disease Type 2 Diabetes

UNKNOWN PHASE4

Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs

NCT01203111

Diabetes Mellitus, Type 2

COMPLETED PHASE4

Insulin Glulisine in Type 2 Diabetic Patients

NCT00360698

Diabetes Mellitus, Type 2

COMPLETED PHASE4

Insulin Glulisine in Diabetes Mellitus, Type 2

NCT00174668

Diabetes Mellitus, Type 2

COMPLETED PHASE3

A Concordance Study Comparing Insulin Treatments in Patients With Type 2 Diabetes

NCT00330473

Diabetes Mellitus, Type 2

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will be randomly assigned to either the control arm and will receive usual AMI care or the experimental arm, which will include routine AMI care as well as intensive therapy intervention.

In addition to the capillary blood glucose measurements obtained to titrate insulin doses in the experimental arm patients, laboratory plasma glucose will be drawn in all patients at randomization, 10, 24, 48, and 72 hours post randomization, 7 days post randomization (or hospital discharge if that occurs first), and 30 days post randomization.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperglycemia Cardiovascular Diseases Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

Patients assigned to the control arm will receive usual care for AMI, according to local practice of each participating centre.

Group Type NO_INTERVENTION

No interventions assigned to this group

Intervention

The experimental arm will have an IV infusion of glulisine insulin started directly after randomization for at least 24 hours and for as long as CCU-level care is required, and the insulin infusion will be adjusted to achieve and maintain a target glucose range of 5.0-6.6 mmol/L (90-118 mg/dL). Once transferred to the ward, patients in the experimental arm will switch to glargine insulin and will continue this treatment for the remainder of their hospitalization and after hospital discharge, for a total duration of 30 days post randomization.

Group Type EXPERIMENTAL

glulisine insulin, glargine insulin

Intervention Type DRUG

IV infusion of glulisine, SC injection of glargine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

glulisine insulin, glargine insulin

IV infusion of glulisine, SC injection of glargine

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Apidra, Lantus

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Both nondiabetic patients and patients with non-insulin-requiring type 2 diabetes mellitus admitted with a suspected AMI are eligible if they meet the following criteria:

* Signs or symptoms of AMI with definite ECG changes, defined as persistent ST-segment elevation (\> or = than 1 mm)in two or more contiguous leads, or new left bundle branch block
* Onset of symptoms within 24 hours before hospital presentation
* Capillary blood glucose level on presentation \> or = 8.0 mmol/L (144 mg/dL)

Exclusion Criteria

* Patient with conditions that REQUIRE the administration of insulin, including:

* Type 1 diabetes mellitus, defined by a documented history of diabetes mellitus before the age of 30
* Type 2 diabetes mellitus that was treated with insulin prior to AMI presentation
* Type 2 diabetes mellitus that is known to be very poorly controlled (e.g. admission capillary blood glucose \> 16.0 mmol/L (288 mg/dL)or marked elevation in glucose for which the site investigator plans to treat with insulin therapy)
* A history of severe hypoglycemic episodes (defined as hypoglycemia with symptoms which the patient is unable to reverse without the assistance of another person) within the past two years
* Known or suspected end-stage liver disease (due to the risk of hypoglycemia in the setting of liver dysfunction and consequent impaired regulation of glucose homeostasis)
* Cardiogenic shock on admission (due to the inaccuracy of glucose meter readings)
* Documented pregnancy
* Any concomitant disease (e.g. cancer) that might limit life expectancy to less than 90 days
* Anticipated poor adherence with study treatments or an other factor that might jeopardize 90-day follow-up (e.g. no fixed address, long distance to hospital, etc.)
* Prior enrollment in this trial or current enrollment in another trial of ST-segment elevation myocardial infarction

Eligible Sex

ALL

Accepts Healthy Volunteers

No